Radiology Case Reports, Journal Year: 2024, Volume and Issue: 19(9), P. 3959 - 3961
Published: July 1, 2024
Language: Английский
Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: unknown
Published: July 17, 2024
Abstract Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the power of immune system against malignant cells. However, their use is associated with a spectrum adverse effects, including cardiovascular complications, which can pose significant clinical challenges. Several mechanisms contribute to toxicity ICIs. First, dysregulation checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) its ligand (PD-L1), molecular mimicry cardiac autoantigens, leads immune-related events, myocarditis vasculitis. These events result from aberrant activation T cells self-antigens within myocardium or vascular endothelium. Second, disruption homeostasis ICIs lead autoimmune-mediated inflammation tissues, manifesting dysfunction heart failure, arrhythmias, pericarditis. Furthermore, upregulation inflammatory cytokines, particularly tumor necrosis factor-alpha, interferon-γ, interleukin-1β, interleukin-6, interleukin-17 contributes endothelial dysfunction, plaque destabilization, thrombosis, exacerbating risk on long term. Understanding intricate side effects induced crucial for optimizing patient care ensure safe effective integration immunotherapy into broader range treatment protocols. The implications these underscore importance vigilant monitoring early detection in patients receiving Future key pathological mediators biomarkers may aid prompt diagnosis cardiotoxicity will allow timely interventions.
Language: Английский
Citations
13
Kidney International, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: Oct. 18, 2024
Background Monoclonal antibodies against programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) have emerged as critical tools in cancer treatment. However, concerns regarding their potential cutaneous and mucosal toxicity, along with severe complications, drawn clinical attention. Further research is warranted to investigate the adverse reactions treatment strategies associated PD-1 monoclonal antibodies. Methods We present a detailed case report of laryngeal patient who developed toxic epidermal necrolysis (TEN) after antibody. analyzed etiology, diagnosis, approaches by integrating manifestations, pathological examinations, literature research. Results After antibody therapy, exhibited systemic rash, bullae, detachment, which subsequently involved tracheal bronchial mucosa, resulting dyspnea. The recovered treatments steroids, macrolides, immunoglobulins, etanercept, repeated removal scabs via bronchoscopy. Literature reviewing suggests association between pathogenesis Steven Johnson’s Syndrome (SJS) Toxic (TEN), possibly due immune dysregulation. Treatment consists immediate discontinuation suspicious drugs, essential supportive corticosteroid administration, addition immunosuppressants and/or immunoglobulins needed. Conclusion mucocutaneous toxicity induced not limited surface skin but also deep layers, potentially leading life-threatening complications. Therefore, when using antibodies, clinicians should closely monitor events apply appropriate soon possible prevent
Language: Английский
Citations
1
La Revue de Médecine Interne, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Citations
1
Lara D. Veeken, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 23, 2024
Abstract Objective To describe presentation, treatment and outcome of immune checkpoint inhibitor (ICI) associated-vasculitis in cancer patients a multicentre study. Methods Thanks to the ImmunoCancer International Registry (ICIR), multidisciplinary network focused on research related adverse events immunotherapies, presenting with clinical and/or radiological suspicion vasculitis histological evidence after being exposed ICIs were retrospectively identified. Results Twenty-eight cases identified ICIR registry. The median interval between starting ICI diagnosis was 4 months. Small vessel predominant (n = 21), followed by large 4) medium 3). small included 10 unclassified either limited cutaneous involvement 6) or systemic 4), five IgA vasculitis, three cryoglobulinemic ANCA+ vasculitis. At presentation during evolution, renal neurologic manifestations evidenced seven each (25%). Renal biopsies documented glomerulopathies six cases. Only (25%) fulfilled 2022 ACR/EULAR classification criteria (four giant cell arteritis, two EGPA one GPA). Most (90%) required corticosteroid an additional drug given (36%). Vasculitis good: 22 had complete response, no patient died due Nine (32%) rechallenged immunotherapy only relapse. Conclusion ICI-associated are rare, heterogeneous, but can be severe requiring urgent management aggressive treatment.
Language: Английский
Citations
1
Radiology Case Reports, Journal Year: 2024, Volume and Issue: 19(9), P. 3959 - 3961
Published: July 1, 2024
Language: Английский
Citations
0